The accelerated adoption of SHINGRIX has led to an unprecedented level of demand.

Healthcare professionals have adopted SHINGRIX and are now vaccinating against shingles at a much higher rate than in previous years.

GSK projects to bring significantly more doses of SHINGRIX into the market in the second half of the year than in the first half of the year.

GSK expects to consistently release doses of SHINGRIX into the market every 2-3 weeks to provide a more predictable and reliable supply experience. As healthcare professionals are vaccinating with SHINGRIX at an unprecedented rate, ordering limits and allocations should still be expected and individual customer resupply experiences will vary.

While demand still exceeds supply, the increased and consistent supply should provide reassurance that patients will have an opportunity to complete the 2-dose series within the 2-6 month dosing window.

There have been no manufacturing issues.

Thank you again for your partnership and commitment to protecting appropriate patients from shingles. Please do not hesitate to contact GSK with any further questions. You may reach us at 1-800-772-9292 or contact your GSK Vaccines Representative today.


SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
  • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
  • Solicited local adverse reactions in subjects aged 50 years and older were pain (78.0%), redness (38.1%), and swelling (25.9%)
  • Solicited general adverse reactions in subjects aged 50 years and older were myalgia (44.7%), fatigue (44.5%), headache (37.7%), shivering (26.8%), fever (20.5%), and gastrointestinal symptoms (17.3%)
  • SHINGRIX was not studied in pregnant or lactating women, and it is unknown if it is excreted in human milk. Therefore, it cannot be established whether there is vaccine-associated risk with SHINGRIX in pregnant women or if there are effects on breastfed infants or milk production/excretion
  • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

All trademarks are the property of their respective owners.

1009805R0 September 2018